CliffBio
small molecule

ZORTRESS

EVEROLIMUS

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameZORTRESS
Active ingredientEVEROLIMUS
Strength0.75MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2010
Marketing statusRX

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.